Literature DB >> 25776027

Accuracy of classifying poorly differentiated non-small cell lung carcinoma biopsies with commonly used lung carcinoma markers.

Susanna Zachara-Szczakowski1, Tyler Verdun1, Andrew Churg2.   

Abstract

Immunohistochemical (IHC) staining is an important adjunct to the classification of non-small cell lung carcinoma (NSCLC). Several studies have used tissue microarrays derived from resection specimens to evaluate the accuracy of IHC staining for classifying NSCLC, but few have used actual biopsies of poorly differentiated carcinomas, and the question of how often biopsy IHC in such tumors leads to the correct classification has received little attention. We identified 40 cases of NSCLC that, on biopsy, could not be subclassified by morphology and that had subsequent resection specimens. TTF-1, napsin, p63/p40, and CK5 or a subset thereof were used for IHC classification. Of the 40 cases classified by IHC on biopsy, 33 (82%) had no change in diagnosis after resection. Of the remaining 7 cases, 3 were classified as NSCLC--not otherwise specified on biopsy and subclassified as either adenocarcinoma or squamous cell carcinoma (SCC) on the surgical specimen. One adenocarcinoma biopsy was reclassified as pleomorphic carcinoma. Two SCCs were changed to adenosquamous carcinoma, and 1 SCC was changed to large cell lung carcinoma. Only 1 antibody pair (2%) was discordant between biopsy, and almost all reclassifications were done based on morphologic features rather than change in IHC pattern. We conclude that IHC staining allows accurate subclassification of poorly differentiated NSCLCs on small lung biopsies in most cases, but there is still a substantial "miss" rate (here, 18%). Surgical resection specimens allow further subclassification, mainly due to architectural features not present in the biopsies.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adenocarcinoma; Biopsy; Immunohistochemistry; Non–small cell lung cancer; Squamous cell carcinoma; Subtyping

Mesh:

Substances:

Year:  2015        PMID: 25776027     DOI: 10.1016/j.humpath.2015.02.001

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  7 in total

Review 1.  The state of the art for artificial intelligence in lung digital pathology.

Authors:  Vidya Sankar Viswanathan; Paula Toro; Germán Corredor; Sanjay Mukhopadhyay; Anant Madabhushi
Journal:  J Pathol       Date:  2022-06-20       Impact factor: 9.883

2.  Utilization of ancillary studies in the cytologic diagnosis of respiratory lesions: The papanicolaou society of cytopathology consensus recommendations for respiratory cytology.

Authors:  Lester J Layfield; Sinchita Roy-Chowdhuri; Zubair Baloch; Hormoz Ehya; Kim Geisinger; Susan J Hsiao; Oscar Lin; Neal I Lindeman; Michael Roh; Fernando Schmitt; Nikoletta Sidiropoulos; Paul A VanderLaan
Journal:  Diagn Cytopathol       Date:  2016-08-26       Impact factor: 1.582

3.  Immune-enrichment of non-small cell lung cancer baseline biopsies for multiplex profiling define prognostic immune checkpoint combinations for patient stratification.

Authors:  Anne Monette; Derek Bergeron; Amira Ben Amor; Liliane Meunier; Christine Caron; Anne-Marie Mes-Masson; Nidhameddine Kchir; Kamel Hamzaoui; Igor Jurisica; Réjean Lapointe
Journal:  J Immunother Cancer       Date:  2019-03-28       Impact factor: 13.751

4.  Lung cancer biopsy: Can diagnosis be changed after immunohistochemistry when the H&E-Based morphology corresponds to a specific tumor subtype?

Authors:  Fabiola Del Carlo Bernardi; Marcela Del Carlo Bernardi; Teresa Takagaki; Sheila Aparecida Coelho Siqueira; Marisa Dolhnikoff
Journal:  Clinics (Sao Paulo)       Date:  2018-10-29       Impact factor: 2.365

Review 5.  Use of Diagnostic Tests in Advanced Non-Small Cell Lung Cancer.

Authors:  Beth Eaby-Sandy
Journal:  J Adv Pract Oncol       Date:  2017-03-01

6.  DeepLRHE: A Deep Convolutional Neural Network Framework to Evaluate the Risk of Lung Cancer Recurrence and Metastasis From Histopathology Images.

Authors:  Zhijun Wu; Lin Wang; Churong Li; Yongcong Cai; Yuebin Liang; Xiaofei Mo; Qingqing Lu; Lixin Dong; Yonggang Liu
Journal:  Front Genet       Date:  2020-08-25       Impact factor: 4.599

7.  Use of dual-marker staining to differentiate between lung squamous cell carcinoma and adenocarcinoma.

Authors:  Rui Guo; Yi Tian; Na Zhang; Hong Huang; Ying Huang; Jun Yang
Journal:  J Int Med Res       Date:  2019-12-27       Impact factor: 1.671

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.